ClinicalTrials.gg
CompletedNCT05011851AS-001Updated Jan 31, 2025

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

A Phase 2 interventional study of NNZ-2591 in Angelman Syndrome, sponsored by Neuren Pharmaceuticals Limited. Completed at 3 sites in Australia. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Neuren Pharmaceuticals Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Study summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Read the detailed description

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution, 50mg/L, in children and adolescents with Angelman syndrome. The secondary purpose is to investigate measures of efficacy of subjects will receive treatment of 50mg/mL orally administered NNZ-2591 for a total of 13 weeks

02

Conditions studied

  • Angelman Syndrome

Browse trials for

Keywords

  • Angelman Syndrome
03

In context

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

This study's enrollment of 17 is below the median of 66 across 29 interventional studies indexed under Angelman Syndrome.

Browse Angelman Syndrome studies →

Lead sponsor

Neuren Pharmaceuticals Limited is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of AS with a documented disease-causing genetic etiology known to impact maternally derived UBE3A expression in brain.
  2. Males or females aged 3-17 years
  3. Body Weight of >12Kg
  4. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 3 or greater
  5. Not actively undergoing regression or loss of skills, defined as no persistent loss of previously acquired developmental skills for a period within 3 months of the Screening visit
  6. Each subject must be able to swallow the study medication provided as a liquid solution.
  7. Caregiver(s) must have sufficient English language skills.

Exclusion criteria

Exclusion Criteria:

  1. Mosaicism for disease-causing mutation.
  2. abnormalities in safety laboratory testing or vital signs at screening
  3. Abnormal interval or prolongation at Screening.
  4. Positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and previous COVID 19 infection with last 12 months that required hospitalization.
  5. Unstable or changes to Psychotropic treatment 2 weeks prior to screening .
  6. Excluded concomitant treatments
  7. Actively undergoing regression or loss of skills.
  8. Unstable seizure profile.
  9. Current clinically significant renal conditions and abnormalities
  10. Current clinically significant cardiovascular, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically significant organ impairment.
  11. Current clinically significant hypo or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.
  12. Has planned surgery during the study.
  13. History of, or current, cerebrovascular disease or brain trauma.
  14. History of, or current catatonia or catatonia-like symptoms.
  15. History of, or current, .
  16. Current major or persistent depressive disorder (including bipolar depression).
  17. Significant, uncorrected visual or uncorrected hearing impairment.
  18. Allergy to strawberry.
  19. Positive pregnancy test
  20. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    NNZ-2591

    NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

    Drug: NNZ-2591

Interventions

  • NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

    Also known as: Cyclo-L-Glycyl-L-2-Allylproline

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.

    Time frame: 13 weeks

  2. Pharmacokinetic - Typical AUC24 of 30kg Child

    Area under the concentration-time curve of NNZ-2591 over 24 hours

    Time frame: 13 weeks

  3. Pharmacokinetic - Typical t1/2 in 30 kg Child

    Apparent terminal elimination half-life of NNZ-2591

    Time frame: 13 weeks

Secondary outcomes

  1. Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)

    Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I). Score on a Likert scale (1-7) where lower scores are better

    Time frame: 13 weeks

  2. Caregiver Impression of Improvement : Overall Score

    Caregiver Impression of Improvement: Overall Score. Measured on a 7-point Likert scale (1-7) where lower scores are better.

    Time frame: 13 weeks

  3. Angelman syndrome-specific Clinical Global Impression Scale - Severity (CGI-S): Overall Score

    Angelman syndrome-specific Clinical Global Impression Scale-Severity (CGI-S): Change from baseline on overall score based on a 7-point Likert scale (1-7) where lower scores are better.

    Time frame: 13 weeks

  4. Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS)

    Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS). Change from baseline in total score based on a 5-point Likert scale (0-4) where lower scores are better.

    Time frame: 13 weeks

  5. Caregiver Top 3 Concerns

    Caregiver Top 3 Concerns: Change from baseline in Average Concerns Severity.

    Time frame: 13 weeks

  6. MacArthur-Bates Communicative Development Inventory (MB-CDI)

    MacArthur-Bates Communicative Development Inventory (MB-CDI)

    Time frame: 13 weeks

  7. Observer-Reported Communication Ability (ORCA)

    Observer-Reported Communication Ability (ORCA). Change from baseline in modified t-score. Scores range from 25.8 - 83.8 with higher scores indicating greater communication abililty. A positive change from baseline indicates improvement

    Time frame: 13 weeks

  8. Aberrant Behavior Checklist-2 (ABC-2)

    Aberrant Behavior Checklist-2 (ABC-2) - Change from baseline in total score. Higher scores indicate more behavioral issues. A negative change from baseline indicates improvement.

    Time frame: 13 weeks

  9. Child Sleep Habits Questionnaire (CSHQ)

    Child Sleep Habits Questionnaire (CSHQ). Change from baseline in total score. Range of scores was (33-99) with higher scores being worse

    Time frame: 13 weeks

  10. Gastrointestinal Health Questionnaire (GIHQ)

    Gastrointestinal Health Questionnaire (GIHQ)

    Time frame: 13 weeks

  11. Vineland Adaptive Behavior Scales-3, Interview version

    Vineland Adaptive Behavior Scales-3, Interview version; Composite standard score

    Time frame: 13 weeks

  12. Exploratory efficacy measurement

    Assessed by Bayley Scales of Infant Development-4, Vineland Motor subscales

    Time frame: 13 weeks

  13. Quality of Life Inventory-Disability (QI-Disability)

    Quality of Life Inventory-Disability (QI-Disability). Change from baseline inoverall score. Scores range from 0-100 with higher scores indicating better quality of life. A positive change indicates improvement

    Time frame: 13 weeks

  14. Impact of Childhood Neurological Disability (ICND)

    Impact of Childhood Neurological Disability (ICND): Change from baseline in overall quality of life rating. Scores range from 1-6, with a higher score indicating better quality of life. A positive change from baseline indicates improvement

    Time frame: 13 weeks

07

Study locations

3 sites
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
  • Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service
    South Brisbane, Queensland 4101, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in May 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2021
First posted
Aug 18, 2021
StartActual
Jul 12, 2022
Primary completionActual
May 13, 2024
CompletionActual
Jul 16, 2024
Results delay requested
Jan 29, 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05011851
Lead sponsor
Neuren Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Jul 12, 2022
Primary completion
May 13, 2024
Completion
Jul 16, 2024
Last update
Jan 31, 2025

Study contacts

James Shaw
study director · Neuren Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ercanetide

Start the discussion